Table 2.
NO | Reference | Model | Acupoints | Acupuncture Parameters | Mechanism | Effects |
---|---|---|---|---|---|---|
1 | Yu, 202374 | Rat | GV14; BL12; BL13 | Once every other day | Reduce p-p38MAPK | Inhibit proliferation of ASMC |
2 | Tang, 202375 | Mouse | GV14, BL12, BL13 | Once a day for 3 days | Reduce IL-4, IL-13, MDA, oxidized GSH, and the non-heme Fe2+ level; downregulate the expression of ACSL4-15-LO1 | Alleviate RL; relieve erastin-induced exacerbation of lung inflammation and lipid peroxidation in ferroptosis |
3 | Tang, 202276 | Rat | BL13; EX-B1; CV17 | Catgut-embedding once | Reduce p38MAPK, ICAM-1, and IL-4 | Inflammatory cells are absent from blood vessels; eosinophils are decreasing |
4 | Teng, 202177 | Mouse | GV14; BL12; BL13 | Catgut-embedding once | Decrease IL-4, IL-13, and IgE in the BALF#; downregulate the expression of p-NF-κB p65 and IFN-γ increase | The percentage of RL increases slower; the percentage of Cdyn decreases slower; the proliferation of ILC2s, leukocytes, eosinophils, lymphocytes, and neutrophils is inhibited |
5 | Yang, 202178 | Human | EX-B1; BL13; ST36; CV17 | Catgut-embedding semimonthly | Decrease IgA and IgE in the serum | PEF, FEV1, MEF25%, MEF50%, MEF75%, and MEF25%–75% are higher than in the control group |
6 | Wang, 202279 | Human | LU9; LU7; LU5 | Three times per week for 4 weeks | N/A | The scores of FEV1, PEF, Asthma control test, and Asthma Quality of Life Questionnaire increase |
7 | Zhao, 202151 | Mouse | GV14; BL13; ST36 | Every other day for 13 days | Downregulate the expression of proteins and mRNAs related to autophagy (ATG5, Beclin-1, p62, and LC3B) and endoplasmic reticulum stress (p-PERK, p-IRE-1, Grp78, and ATF6); increase in IFN-γ and decrease in IL-4, IL-17, and TGF-β in the BALF, lung tissue, and serum | Inflammatory cells decrease; suppressed level of autophagy and endoplasmic reticulum stress; balance of Th1/Th2 and Treg/Th17; RL decrease |
8 | Qiao, 202180 | Mouse | BL13; LU1 | Once daily for 2 weeks | Reduce IgE and IL-4 and increase IFN-γ; upregulate the expression of PI3K, Foxp3, and ROR gammat | Suppress inflammatory responses |
9 | Zheng, 202181 | Rat | GV14; BL12; BL13 | Once a day for 7 days | Downregulate the expression of Bcl-2 and upregulate the expression of Fas | Reduce eosinophils and enhance apoptosis of eosinophils |
10 | Tang, 202145 | Mouse | GV14; BL12; BL13 | Retained for 20 min | Reduce IgE, CCL5, CCL11, and IL-17A in BALF and IL-4, IL-5, and IL-13 in serum; downregulate the expression of SLC3A2 and ATP1A3; enhance the level of SOD and GSH, and lower the level of MDA | Relieve RL and enhance Cdyn; decrease the inflammatory score, PAS+ epithelial cells, and eosinophils |
11 | Hu, 202046 | Rat | GV14; BL12; BL13 | Once a day for 7 days | Downregulate the expression of CCL1, CCR8, and STAT6 | Reduce inflammatory responses |
12 | Cheng, 202182 | Human |
|
Retained for 30 min | N/A | FEV1, PEF, The Self-rating Anxiety Scale, and Self-rating Depression Scale are improved |
13 | Yu, 202083 | Human |
|
Three times a week | N/A | Improve the Asthma Control Test (ACT), the peak expiratory flow rate (PEFR), and forced expiratory volume in 1 s (FEV1) |
14 | He, 202184 | Rat | GV14; BL12; BL13 | Once a day for 7 times | Downregulate the expression of FIZZ1, NOTCH1, and α-SMA | Inhibit the differentiation of fibroblasts, reduce the proliferation of smooth muscle |
15 | Cui, 202143 | Mouse | GV14; BL12; BL13 | Every other day for 2 weeks | Reduce IL-5, IL-9, IL-13, IL-25, IL-33, and soluble IL-33 receptor (sST2) | Relieve RL and enhance Cdyn; decrease the inflammatory score, PAS+ epithelial cells, and eosinophils; inhibit the proliferation of ILC2s |
16 | Zhou, 202085 | Rat | GV14; BL12; BL13 | Every other day for 13 days | Upregulate the expression of MT-2, Akt1, and CaMK2β; induced phosphorylation of 14 proteins is upregulated, while that of 37 proteins is downregulated | Relieve RL |
17 | Hua, 202050 | Rat | GV14; ST36; BL13 | Retained for 20 min | Downregulate IL-5 and GATA-3 and upregulate IFN-γ and T-bet | Balance Th1/Th2; suppress inflammation responses |
18 | Chen, 202086 | Rat | GV14; BL12; BL13 | 30 min a day on every other day | Increase cAMP/cGMP and substance P; downregulate vasoactive intestinal peptide, neurokinin A, and neurokinin B | Alleviate neurogenic inflammation and hyperresponsiveness of the airway |
19 | S. Elsheikh, 201987 | Human | LU5; LU7; LU9; SP6; ST36; BL13; BL23; CV17; GV14 | N/A | N/A | Relieve RL |
20 | Dong, 201952 | Mouse | GV14; BL12; BL13 | Every other day for 4 weeks | Upregulate T-bet, FOXP3+, and IL-10, and reduce IL-5, IL-13, IL-17A, and RAR-related orphan receptor gamma t (RORγt) | Upregulate the cell numbers of CD4+ interferon gamma (IFN-γ)+, CD4+ Foxp3+, and CD4+ IL-17A+; balance CD4+ T cell subtypes |
21 | Nurwati, 201988 | Mouse | BL13; ST36 | Three times a week for 6 weeks | N/A | Reduce neutrophils, eosinophils, and goblet cells; reduce thickness of the bronchioles |
22 | Liu, 201889 | Mouse | GV14; BL13; ST36 | Once a day for three days | Reduce TGF-β1 in BALF and downregulate the expression of Smads, type-I, and α-SMA | Relieve RL |
23 | Dong, 201890 | Mouse | GV14; BL12; BL13 | Every other day for 2 weeks | Reduce TNF-α, IL-1β, and IL-33; increase sST2 | Relieve RL and enhance Cdyn; reduce the inflammatory responses, PAS+ epithelial cells, and CD4 +IL-17A+ (Th17) cells; |
24 | Han, 201891 | Human | LU6; EX-B1; BL13; LU10 | Retained for 20 min | Reduce NGF and MMP-9 | Upregulate Th1/Th17; relieve FEV1, PEF, FEV1/FEV |
25 | Chen, 201792 | Rat | BL13; BL23 | Retained for 30 min, once daily for 14 days | Reduce IL-1β and IgE | Reduce CD8+ T cells; relieve inflammatory responses |
26 | Yang, 201793,94 | Rat | GV14; BL13; BL12 | Once every two days, for seven times | Downregulate the expression of Akt and p-Akt | Relieve inflammatory responses |
27 | Xu, 201795 | Rat | GV14; BL13; BL12 | Acupuncture for 15 min or 30 min | N/A | Inhibit ACh-induced contractile responses of airway smooth muscle cells (ASMCs) |
28 | Yang, 201796 | Rat | GV14; BL13; BL12 | Retained for 20 min, once other day | Downregulate the expression of PI3K | Relieve RL and Cdyn |
29 | A. Dabbous, 201719 | Human | CV17; LU5; LU7; LU9; ST36; SP6; GV14; BL13; BL23; LI4 | Laser acupuncture for 2 min per point; three sessions per week | N/A | Relieve FEV1 and FVC |
30 | Wei, 201797 | Mouse | GV14; BL13; BL12 | Every other day for 4 weeks | Reduce TNF-α, IL-1β, IL-5, and eotaxin; increase CORT and ACTH | Relieve RL and inflammatory cells, enhance Cdyn |
31 | Wang, 201698 | Rat | GV14; BL13; BL12 | Retained for 20 min | Increase CORT | Relieve RL and eosinophils |
32 | Yu, 201699,100 |
Rat | GV14; BL13; BL12 | Once other day for 14 days | Reduce TGF-β, c-fos; downregulate p-p38MAPK | Reduce leukocytes and eosinophils; relieve RL |
33 | Dong, 201573 | Mouse | GV14, BL12, BL13, BL23 | Three times a week for 6 weeks | Reduce IL-17A, IL-4, and IL-5 in BALF and serum; increase IFN-γ and IL-10 | Relieve RL and enhance Cdyn; lower inflammatory score |
34 | Wei, 201553 | Mouse | GV14; BL13; BL12 | Every other day for 4 weeks | Reduce IL-17A, IL-17F, IL-22, and IgE; suppress the expression of IL-17R, RORγt, p65, and NF-κB kinase-α (IKKα) | Relieve RL and enhance Cdyn; reduce leukocytes, eosinophils, neutrophils, and CD4+IL-17A+ cell numbers, and increase CD4+Foxp3+ cell numbers in BALF |
35 | Ke, 2015101 | Human | BL13; CV17; LI4; GV14; ST40; LU1; LU6 | Once a day for three days | Reduce C-RP, Ig E, IL-1, IL-6, and TNF-α in the serum | Relieve the syndrome of asthma |
36 | Li, 2014102 | Rat | GV14; BL13; BL12 | Once a day for 10 days | Reduce TGF-β in the lung | Decrease the thickness of the airway wall and smooth muscle |
37 | Tang, 2014103 | Mouse | GV14; BL13; BL12; EX-B1; BL23; BL20 | Once a day for 7 days | Reduce thymic stromal lymphopoietin (TSLP) and GATA; increase T-bet | Decrease the thickness of the airway wall and smooth muscle |
38 | Ngai, 2013/ 2011104,105 | Human | BL13/LU7; LU9 | N/A | N/A | Decrease the skin impedance and heart rate variability (LF/HF)/increase the skin impedance at LU7 and LU9 |
39 | Fu, 2014/ 2013; Zhu, 2013; Tan, 201210,106–108 | Human | LU1, LU5, LU7; LI11, LI4, ST25; LU5, LU7, LI4, ST25 | Every other day, three times a week for 12 weeks | N/A | Improve PEF, FEV1, MEF25%, MEF50%, and MEF75% |
40 | Wang, 2014109 | Rat | GV14; BL13; BL12 | Once every two days, for seven times | Reduce p38MAPK | Reduce eosinophils |
41 | Yang, 201371 | Human | GV14; BL13; BL12 | Once every other day for 5 weeks | Reduce secretory IgA (sIgA) and total IgA in the saliva and IgE in the serum | Reduce CD3+, CD4+, CD8+, IL-2R+ T lymphocytes, and eosinophils |
42 | Cui/ Yang 2013110,111 | Rat | GV14; BL13; BL12 | Once a day for 7 days | Reduce pan-Ras and c-fos/ reduce c-fos and p38MAPK | Relieve the syndrome of asthma |
43 | Yin, 2010/ 2009112,113 | Rat | GV14; BL13; BL12 | Five consecutive days | Reduce Dusp1, S100A9, and MT-2 | Relieve the syndrome of asthma |
44 | Chen, 2012114 | Rat | BL13, BL23, CV17; BL23; BL13, CV17 | Catgut-embedding once | N/A | Relieve inflammatory responses |
45 | Wang, 2012115 | Rat | GV14; BL13; BL12 | Once two days for seven times | Reduce Cav3.3 | Relieve inflammatory responses |
46 | E.R. Carneiro, 2010116 | Rat | GV14, BL13, EX-B1, LU1, CV17, ST36, SP6 | Every other day for 2 weeks | Increase IL-1, IFN-γ, and IL-4; reduce NO, IL-10, and LTB4 | Balance Thl/Th2 |
47 | Yan, 2010117 | Rat | GV14; BL13; BL12 | Once two days for seven times | Increase surfactant protein-A in BALF | Relieve the syndrome of asthma |
Abbreviations: #BALF, bronchoalveolar lavage fluid; RL, airway resistance; Cdyn, lung dynamic compliance.